SCHEMBL19686838

SCHEMBL19686838

CC(C)(C)OC(=O)N1CC(Oc2cc(N(C(=O)OC(C)(C)C)C3CCC(F)(F)CC3)nc(-c3nc(C(F)F)cs3)n2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 4/20 0.38
GPR119 Q8TDV5 6/20 0.35
USP30 Q70CQ3 2/20 0.33
IDH2 P48735 1/20 0.32
CACNB4 O00305 1/20 0.31
CACNA1A O00555 1/20 0.31
CACNA1G O43497 1/20 0.31
CACNG3 O60359 1/20 0.31
CACNA1F O60840 1/20 0.31
CACNA1H O95180 1/20 0.31
CACNB3 P54284 1/20 0.31
CACNA2D1 P54289 1/20 0.31
CACNG7 P62955 1/20 0.31
CACNA1B Q00975 1/20 0.31
CACNA1D Q01668 1/20 0.31
CACNB1 Q02641 1/20 0.31
CACNG1 Q06432 1/20 0.31
CACNB2 Q08289 1/20 0.31
CACNA1S Q13698 1/20 0.31
CACNA1C Q13936 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19687228 0.94 GPR119 (0.35) IDH1GPR119USP30IDH2CACNB4
SCHEMBL31127410 0.94 GPR119 (0.35) IDH1GPR119USP30IDH2CACNB4
SCHEMBL31127284 0.90 GPR119 (0.36) IDH1GPR119USP30IDH2CACNB4
SCHEMBL19687469 0.90 GPR119 (0.36) IDH1GPR119USP30IDH2CACNB4
SCHEMBL19687515 0.90 IDH1 (0.39) IDH1GPR119USP30IDH2CACNB4
SCHEMBL19686841 0.90 GPR119 (0.36) IDH1GPR119USP30IDH2CACNB4
SCHEMBL19687229 0.89 GPR119 (0.35) IDH1GPR119USP30IDH2CACNB4
SCHEMBL31127130 0.89 GPR119 (0.35) IDH1GPR119USP30IDH2CACNB4
SCHEMBL19686842 0.88 GPR119 (0.35) IDH1GPR119USP30IDH2CACNB4
SCHEMBL31127149 0.88 GPR119 (0.35) IDH1GPR119USP30IDH2CACNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885GPR119 236/4885USP30 3858/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885GPR119 236/4885USP30 3858/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885GPR119 236/4885USP30 3858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.